1. A Bayesian adaptive marker‐stratified design for molecularly targeted agents with customized hierarchical modeling. (9th April 2019) Authors: Zang, Yong; Guo, Beibei; Han, Yan; Cao, Sha; Zhang, Chi Journal: Statistics in medicine Issue: Volume 38:Number 15(2019) Page Start: 2883 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Bayesian adaptive phase II clinical trial design accounting for spatial variation. (November 2019) Authors: Guo, Beibei; Zang, Yong Journal: Statistical methods in medical research Issue: Volume 28:Number 10/11(2019) Page Start: 3187 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A Bayesian dose‐finding design for phase I/II clinical trials with nonignorable dropouts. (28th January 2015) Authors: Guo, Beibei; Yuan, Ying Journal: Statistics in medicine Issue: Volume 34:Number 10(2015) Page Start: 1721 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy. (June 2022) Authors: Guo, Beibei; Zang, Yong Journal: Statistical methods in medical research Issue: Volume 31:Number 6(2022) Page Start: 1104 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A Bayesian phase I/II design for cancer clinical trials combining an immunotherapeutic agent with a chemotherapeutic agent. Issue 5 (14th June 2021) Authors: Guo, Beibei; Garrett‐Mayer, Elizabeth; Liu, Suyu Journal: Journal of the Royal Statistical Society Issue: Volume 70:Issue 5(2021) Page Start: 1210 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. A Bayesian Phase I/II Design for Cancer Clinical Trials Combining an Immunotherapeutic Agent with a Chemotherapeutic Agent. Issue 5 (17th November 2021) Authors: Guo, Beibei; Garrett-Mayer, Elizabeth; Liu, Suyu Journal: Journal of the Royal Statistical Society Issue: Volume 70:Issue 5(2021) Page Start: 1210 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. A Bayesian phase I/II design to determine subgroup‐specific optimal dose for immunotherapy sequentially combined with radiotherapy. (26th September 2022) Authors: Guo, Beibei; Zang, Yong; Lin, Li‐Hsiang; Zhang, Rui Journal: Pharmaceutical statistics Issue: Volume 22:Number 1(2023) Page Start: 143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. A Bayesian Phase I/II Trial Design for Immunotherapy. Issue 523 (3rd July 2018) Authors: Liu, Suyu; Guo, Beibei; Yuan, Ying Journal: Journal of the American Statistical Association Issue: Volume 113:Issue 523(2018) Page Start: 1016 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. A bimetallic MOF@graphene oxide composite as an efficient bifunctional oxygen electrocatalyst for rechargeable Zn–air batteries. Issue 17 (22nd April 2020) Authors: Xiao, Yao; Guo, Beibei; Zhang, Jing; Hu, Chun; Ma, Ruguang; Wang, Deyi; Wang, Jiacheng Journal: Dalton transactions Issue: Volume 49:Issue 17(2020) Page Start: 5730 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. A comparative review of methods for comparing means using partially paired data. (June 2017) Authors: Guo, Beibei; Yuan, Ying Journal: Statistical methods in medical research Issue: Volume 26:Number 3(2017) Page Start: 1323 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗